Loading
Krystal Biotech, Inc. Stock: price and insider trades · United States
Krystal Biotech, Inc.: what insiders have been doing
Headquartered in United States, Krystal Biotech, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 9 insiders have disclosed 52 filings since 18 October 2025.
Only sales appear on the open market, 40 sales in all totalling €25.3M, filed by 5 insiders. The totals exclude 1 filing filed without an amount. At €2.2M, the sale published on 3 March 2026 by Janney Daniel is the largest of the period.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 52 filings here. Our records for Krystal Biotech, Inc. go back to 2021, with no purchases and 81 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 389.1 m USD and net income of 204.8 m USD.
Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
119
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€65M
81 ops. · all time
Who traded when
BuySaleKrish S. Krishnan19 sales
Suma Krishnan19 sales
Rossi Dino A8 sales
Janney Daniel1 sale
Thomas John Charles1 sale
Analyst consensus: bullish or bearish?
Analysts rate Krystal Biotech, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$392.11.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,788 of 24,148 companies
62.5
score / 100
Value32
Quality93
FCF yld1.9%
Earn yld2.1%
EV/EBITDA58.4x
ROE20%
Gross mgn94%
Net mgn53%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$330.69
Analyst consensus
9 analystsStrong buy
US$284.00Target US$392.11(+19%)US$474.00
Income statement
RevenueUS$389.1M
Gross profitUS$366.1M94% margin
EBITDAUS$167.8M43% margin
Net incomeUS$204.8M54.8% margin
Valuation
PER (trailing)40.2x
PER (forward)36.1x
P/Book7.2x
Beta0.50
Balance sheet & cash
Market capUS$9.8B
Total debtUS$9.3M
Free Cash FlowUS$188.9M
Debt / Equity1%
Profitability & ownership
ROE20.1%
ROA9.4%
% insiders10.7%
% institutions102.4%
Last declaration on 4 September 2026
Declarations119 total
25,000 shares@ US$371.470.090% mcap55.2% of flowCommonSEC144:0001950047-26-009148
25,000 shares@ US$371.470.090% mcap55.2% of flowCommonSEC144:0001950047-26-009149
520 shares@ US$354.540.0018% mcap0.6% of flowCommon StockSEC:0001298709-26-000011:0
3,981 shares@ US$357.57380.014% mcap4.5% of flowCommon StockSEC:0001298709-26-000011:3
3,357 shares@ US$359.38610.012% mcap3.8% of flowCommon StockSEC:0001298709-26-000011:5
1,358 shares@ US$364.47940.0048% mcap1.6% of flowCommon StockSEC:0001298709-26-000011:10
3,180 shares@ US$358.42030.011% mcap3.6% of flowCommon StockSEC:0001298711-26-000009:4
826 shares@ US$365.41390.0029% mcap0.9% of flowCommon StockSEC:0001298711-26-000009:11
2,029 shares@ US$355.57190.0070% mcap2.3% of flowCommon StockSEC:0001298709-26-000011:1
3,297 shares@ US$356.36870.011% mcap3.7% of flowCommon StockSEC:0001298709-26-000011:2
3,143 shares@ US$358.41820.011% mcap3.5% of flowCommon StockSEC:0001298709-26-000011:4
2,266 shares@ US$360.4630.0079% mcap2.6% of flowCommon StockSEC:0001298709-26-000011:6
1,214 shares@ US$361.60910.0042% mcap1.4% of flowCommon StockSEC:0001298709-26-000011:7
2,010 shares@ US$362.65040.0071% mcap2.3% of flowCommon StockSEC:0001298709-26-000011:8
573 shares@ US$363.34240.0020% mcap0.7% of flowCommon StockSEC:0001298709-26-000011:9
847 shares@ US$365.41630.0030% mcap1.0% of flowCommon StockSEC:0001298709-26-000011:11
405 shares@ US$366.55670.0014% mcap0.5% of flowCommon StockSEC:0001298709-26-000011:12
520 shares@ US$354.540.0018% mcap0.6% of flowCommon StockSEC:0001298711-26-000009:0
2,006 shares@ US$355.57190.0069% mcap2.2% of flowCommon StockSEC:0001298711-26-000009:1
3,267 shares@ US$356.36790.011% mcap3.6% of flowCommon StockSEC:0001298711-26-000009:2
3,962 shares@ US$357.57420.014% mcap4.4% of flowCommon StockSEC:0001298711-26-000009:3
3,392 shares@ US$359.38620.012% mcap3.8% of flowCommon StockSEC:0001298711-26-000009:5
2,320 shares@ US$360.4660.0081% mcap2.6% of flowCommon StockSEC:0001298711-26-000009:6
1,242 shares@ US$361.610.0043% mcap1.4% of flowCommon StockSEC:0001298711-26-000009:7
1,992 shares@ US$362.65270.0070% mcap2.3% of flowCommon StockSEC:0001298711-26-000009:8
25 of 119 declarations
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a U.S.-based biotechnology company listed on the NASDAQ in the United States, with headquarters in Pittsburgh, Pennsylvania. Founded originally as Krystal Biotech, LLC and later reorganized as a corporation in 2017, the company has been built around a proprietary platform using modified, replication-defective, non-integrating HSV-1 vectors. Its core strategy is to develop redosable gene therapies for severe rare diseases with limited or no approved treatment options. For investors, Krystal represents a specialized, science-driven biotech with a vertically integrated model that combines R&D, manufacturing, and selective commercialization. ([krystalbio.com](https://www.krystalbio.com/?utm_source=openai))
Krystal’s commercial anchor is VYJUVEK (beremagene geperpavec-svdt, or B-VEC), approved for dystrophic epidermolysis bullosa (DEB). The company describes VYJUVEK as its first commercial product and the first redosable gene therapy approved in major jurisdictions including the United States, Europe, and Japan. That makes Krystal unusual among small- to mid-cap biotech names: it is no longer a pure development-stage story, but a commercial rare-disease company with an established revenue base and an expanding global footprint. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-first-quarter-2026-financial-and?utm_source=openai))
Read moreShow less
Competitively, Krystal’s edge comes from product differentiation and platform depth rather than scale. VYJUVEK’s commercial progress has given the company an early-mover position in DEB, while the broader pipeline provides optionality across dermatology, oncology, and other rare or genetically defined conditions. Krystal also operates two GMP facilities, which supports manufacturing control and may reduce reliance on third parties as demand scales. For investors, this vertical integration is important because it can improve supply resilience and operational visibility, although execution risk remains typical of specialty biotech. ([krystalbio.com](https://www.krystalbio.com/?utm_source=openai))
Geographically, the company is anchored in Pittsburgh but increasingly international in ambition. In 2025 and 2026, Krystal highlighted ongoing commercialization of VYJUVEK in the United States, Europe, and Japan, and described a specialty-distributor network covering additional regions such as the Middle East, Turkey, and Central and Eastern Europe. The implication is clear: management is building a global rare-disease franchise rather than relying solely on the U.S. market. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-third-quarter-2025-financial-and?utm_source=openai))
Recent developments have been constructive. In early 2026, Krystal reported strong VYJUVEK revenue growth and reiterated the strength of its balance sheet, while also pointing to multiple pipeline catalysts. Management highlighted expected 2026 readouts for KB803 and KB801, and the FDA granted platform technology designations for KB407 and KB111. The company also received RMAT designation for KB707 in advanced or metastatic non-small cell lung cancer, underscoring that the platform is being extended beyond dermatology. For a Form 4-driven investor audience, these updates matter because insider activity should be interpreted alongside commercial momentum, pipeline execution, and the company’s ability to convert scientific credibility into additional approved products. ([ir.krystalbio.com](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-first-quarter-2026-financial-and?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
